ClinicalTrials.gg
RecruitingNCT06324396IMPROVE-FALDUpdated Nov 2, 2026

IMProving DRug Dosing and Outcomes for Single VEntricle Patients With Fontan Associated Liver Disease

A Phase 1 interventional study of Sildenafil 10mg oral tablet (participants <20kg), or 20mg oral tablet (participants ≥20kg) and Pravastatin 20 mg oral tablet (ages <13 years), or 40 mg oral tablet (≥14 years) in Fontan Circulation, sponsored by Children's Mercy Hospital Kansas City. Recruiting at 1 site in United States. Open to participants aged 8 Years and older. Per ClinicalTrials.gov, last updated 2026-11-02.

Sponsored by Children's Mercy Hospital Kansas City · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Mar 2024; still recruiting 2 years 8 months later.
Updated Nov 2, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
15
Allocation
Not applicable
Ages
8 Years and older
Sex
All
01

Study summary

This is a single center, open-label, prospective, investigation to quantify the effects liver congestion and fibrosis has on hepatic drug metabolism and transport in children, adolescents, and young adults with Fontan circulation.

02

Conditions studied

  • Fontan Circulation

Keywords

  • Fontan
  • FALD
03

In context

Lead sponsor

Children's Mercy Hospital Kansas City is the lead sponsor of 210 studies on the registry; 20 are open to participants now.

Of its 18 completed or terminated interventional studies of FDA-regulated products, 14 (78%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
8 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • > 8 years
  • Status Post Fontan Completion
  • Ability to provide informed permission-assent (\<18 years) or consent (≥18 years)
  • Fasting overnight (\~8 hours)

Exclusion criteria

Exclusion Criteria:

  • Pregnancy
  • Non-fasting
  • Non-removable metal in body or where magnetic resonance imaging (MRI) is considered unsafe
  • Sildenafil and/or Pravastatin therapy within last 2 months
  • History of underlying or laboratory evidence of underlying intestinal, metabolic, , renal disease that can alter Sildenafil and Pravastatin disposition (absorption, metabolism, distribution, or clearance)
  • Pharmacotherapy that interacts with Sildenafil (cytochrome P450 3A4 and P450 3A5 (/5) inducers/inhibitors) and/or Pravastatin (organic anion transporting polypeptide (OATP1B1) inducers/inhibitors)
  • Inability to swallow a tablet
  • >5X the age-specific for (AST) and alanine aminotransferase (ALT), total and conjugated
  • Diarrhea in the last 24 hours *History of solid organ transplantation
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
15 participants (estimated)

Study arms

  • Experimental
    Assessment Arm

    Assessment group will receive a single dose of oral sildenafil and oral pravastatin.

    Drug: Sildenafil 10mg oral tablet (participants <20kg), or 20mg oral tablet (participants ≥20kg) · Drug: Pravastatin 20 mg oral tablet (ages <13 years), or 40 mg oral tablet (≥14 years)

Interventions

  • DrugSildenafilStudies of SildenafilSildenafil pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    A single oral dose of sildenafil will be administered to all study subjects.

  • DrugPravastatinStudies of PravastatinPravastatin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    A single oral dose of pravastatin will be administered to all study subjects.

06

What researchers measure

Primary outcomes

  1. Sildenafil concentration as measured by area under the curve (AUC)

    Area under the time-exposure curve (AUC 0-n) for sildenafil as determinants of the dose-exposure relationship.

    Time frame: 2 years

  2. Pravastatin concentration as measured by area under the curve (AUC)

    Area under the time-exposure curve (AUC 0-n) for pravastatin as determinants of the dose-exposure relationship.

    Time frame: 2 years

07

Study locations

1 of 1 sites recruiting
  • Children's Mercy Hospital
    Kansas City, Missouri 64108, United States
    Recruiting
    • Jonathan Wagner, DO · Contact
    • Jonathan Wagner, DO · Principal investigator
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Mar 2024 (actual). Primary completion is estimated for May 2027, 38 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 2, 2026: primary completion Dec 2026 → May 2027 and completion Dec 2026 → Dec 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 14, 2024
First posted
Mar 22, 2024
StartActual
Mar 1, 2024
Primary completionEst.
May 31, 2027was Dec 2026
CompletionEst.
Dec 31, 2027was Dec 2026
Last update
Nov 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Dec 31, 2026→May 31, 2027
Nov 2, 2026
Study completion
Dec 31, 2026→Dec 31, 2027
Nov 2, 2026
Show all 1 update
  1. Nov 2, 2026
    Primary completion Dec 31, 2026→May 31, 2027
    Study completion Dec 31, 2026→Dec 31, 2027
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT06324396
Collaborators
Indiana Clinical and Translational Sciences Institute, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Responsible party
Jon Wagner (Director, Division of Clinical Pharmacology, Toxicology, and Therapeutic Innovation, Children's Mercy Hospital Kansas City) — Principal investigator
First posted
Mar 22, 2024
Start date
Mar 1, 2024
Primary completion
May 31, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Nov 2, 2026

Study contacts

Jonthan Wagner, DO
Contact
jbwagner@cmh.edu
816-731-7240
Jonathan Wagner, DO
principal investigator · Children's Mercy

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Sildenafil · Pravastatin

Start the discussion